Interstitial Cystitis – Epidemiology Insights -2023” Reports
provides an overview of the disease. The Report includes global forecast of
epidemiology of Interstitial Cystitis till 2023. Interstitial cystitis (IC)
also known as painful bladder syndrome is a chronic disease that results in
recurring discomfort or pain in the bladder and the surrounding pelvic region.
This is considered as multiple bladder condition as it can
lead to many other problems. Current studies estimate that 2.7% to 6.5% of
women in the United States have symptoms consistent with a diagnosis of
interstitial cystitis/bladder pain syndrome (IC/BPS). PBS/IC is more common in
women, with a female/male ratio that ranges from 5:1 to 10:1 and the Median age
at diagnosis is 42 to 46 yr old whereas men are diagnosed at a younger age.
According to Publisher, the number of Incident Probable IC
cases in 7 major markets is expected to reach 1,97,086 cases in 2023. The
report is built using data and information sourced from proprietary databases,
primary and secondary research and in-house Forecast model analysis by
Publisher team of industry experts.
Scope
- The report will help in developing business strategies by understanding the trends shaping and driving the global Interstitial Cystitis scenario.
- Review of the key market drivers and barriers.
- To understand the regulatory scenario in major markets.
- The Report covers the detailed global historical and forecasted Interstitial Cystitis Epidemiology covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Spanning over 51 pages “Interstitial Cystitis
- Epidemiology Insights -2023” report covers Report Introduction,
Interstitial Cystitis, Epidemiology and Patient Population, Assumptions and
Caveats, Market Drivers, Appendix.
For
more information Visit at: http://mrr.cm/USa
Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.